文献速递泌尿生殖与妇科肿瘤放疗

宫颈癌术后辅助治疗:网络Meta分析

Postoperative Adjuvant Treatments for Cervical Cancer: A Network Meta-Analysis.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-07-31

CCRT+CT在总生存(HR 0.46,95%CI 0.28-0.71)和无病生存(HR 0.48,95%CI 0.23-0.91)及复发(RR 0.45,95%CI 0.15-0.83)方面显示最显著获益,但不良事件无显著差异,RT在减少不良事件方面排名最优。

要点

  • CCRT+CT对总生存获益最显著(HR 0.46,95%CI 0.28-0.71,高确定性证据)。
  • CCRT+CT对无病生存和复发也有显著优势,但证据确定性较低。
  • 各治疗间不良事件风险无显著差异,RT在减少不良事件方面排名最优。

核心结论

  • 在早期宫颈癌术后辅助治疗中,CCRT+CT在改善总生存、无病生存和减少复发方面显示最有利趋势,尤其在高危特征患者中。

主要发现

  • CCRT+CT对总生存获益最显著(HR 0.46,95%CI 0.28-0.71,SUCRA 95%,高确定性证据)。
  • CCRT+CT对无病生存显著优于RT(HR 0.48,95%CI 0.23-0.91,SUCRA 88%,低确定性证据)。
  • CCRT+CT对复发风险降低最显著(RR 0.45,95%CI 0.15-0.83,SUCRA 85%)。
  • 远处复发或转移在各治疗间无统计学显著差异。
  • 骨髓抑制、直肠炎、膀胱炎和恶心呕吐等不良事件风险在各治疗间无显著差异。

关键数值与推荐

  • CCRT+CT vs 其他:总生存HR 0.46(95%CI 0.28-0.71),SUCRA 95%,高确定性证据。
  • SCRT vs 其他:总生存HR 1.59(95%CI 1.04-2.33),SUCRA 65%,高确定性证据。
  • CCRT vs 其他:总生存HR 0.71(95%CI 0.5-0.95),SUCRA 48%,中等确定性证据。
  • CCRT+CT vs RT:无病生存HR 0.48(95%CI 0.23-0.91),SUCRA 88%,低确定性证据。
  • CCRT+CT复发RR 0.45(95%CI 0.15-0.83),CCRT复发RR 0.59(95%CI 0.24-0.97),SCRT复发RR 1.17(95%CI 1.01-3.28)。

临床怎么用

  • 对于具有高危特征的早期宫颈癌术后患者,可考虑CCRT+CT以改善生存和减少复发。
  • 选择治疗方案时需权衡疗效与不良事件,RT在减少不良事件方面可能更有利。
  • 具体亚组治疗决策仍需进一步高质量研究确认。

局限性

  • 部分结局的证据确定性较低,需更多高质量研究验证。
  • 特定亚组的治疗决策尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to perform a comprehensive network meta-analysis assessing the efficacy and safety of 5 postoperative adjuvant therapies (PATs) for early-stage cervical cancer, comparing their effects on survival and adverse outcomes to identify the therapy with the most significant survival benefit. We comprehensively searched PubMed, Web of Science, the Cochrane Library, Embase, CNKI, VIP, Wanfang, and CBM for randomized controlled trials on PATs-including concurrent chemoradiation therapy (CCRT), radiation therapy (RT), chemotherapy (CT), sequential chemoradiation therapy (SCRT), and CCRT followed by consolidation chemotherapy (CCRT + CT)-in patients with cervical cancer from inception to October 2024. Study bias was assessed with the Cochrane ROB.2. A Bayesian random-effects network meta-analysis was conducted for indirect comparisons, with τ2 used to evaluate heterogeneity. Treatment rankings were generated using the surface under the cumulative ranking (SUCRA) curve, and evidence certainty was assessed with the Confidence in Network Meta-Analysis framework. Nineteen randomized controlled trials with a total of 2937 patients met the inclusion criteria. In our network meta-analysis, CCRT + CT showed the most significant benefit for overall survival (hazard ratios [HR], 0.46; 95% CI, 0.28-0.71; SUCRA 95%, high-certainty evidence), followed by SCRT (1.59; 95% CI, 1.04-2.33; SUCRA 65%, high-certainty evidence) and CCRT alone (HR, 0.71; 95% CI, 0.5-0.95; SUCRA 48%, moderate-certainty evidence). For disease-free survival, CCRT + CT again showed a significant advantage over RT (HR, 0.48; 95% CI, 0.23-0.91; SUCRA 88%, low-certainty evidence). In recurrence analysis, CCRT + CT demonstrated the most substantial reduction in relative risk (RR, 0.45; 95% CI, 0.15-0.83; 85%), followed by CCRT (RR, 0.59; 95% CI, 0.24-0.97; SUCRA 68%) and SCRT (RR, 1.17; 95% CI, 1.01-3.28; SUCRA 40%). No statistically significant differences were observed for distant recurrence or metastasis among the therapies; however, SUCRA rankings indicated that CCRT + CT and CCRT might offer some benefit in reducing these outcomes. For adverse events-specifically myelosuppression, proctitis, cystitis, and nausea/vomiting-no significant differences in risk were observed across therapies. However, SUCRA rankings favored RT as the most favorable option for minimizing these events. This study provides a comprehensive assessment of PATs for early-stage cervical cancer. Among the evaluated options, CCRT + CT showed the most promising trend toward improving overall and disease-free survival and reducing recurrence, particularly in patients with high-risk features. However, further high-quality studies are needed to confirm these findings and guide treatment decisions for specific subgroups.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Huang W, Fang X, Ou X, et al. Postoperative Adjuvant Treatments for Cervical Cancer: A Network Meta-Analysis. Int J Radiat Oncol Biol Phys. 2025. PMID: 40752650. doi:10.1016/j.ijrobp.2025.07.1440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。